To clock Rs 1500cr in revenues for 2013-14: Shasun Pharma

Shasun Pharmaceuticals has big capacity expansion plans for 2013-14. Speaking to CNBC-TV18, managing director Abhaya Kumar says the company is planning an investment of more than Rs 250 crore towards achieving this aim.

UK biz strong; see FY13 revenue at Rs 1,200cr: Shashun

Shasun Pharma is one of the key suppliers to Vertex for Hepatitis C drug -Incivek, which has received a US Food & Drug Administration (USFDA) 'Black Box' warning. This warning indicates that if one gets severe rash symptoms then the drug should be stopped using immediately.

Capacity debottlenecking led to growth: Shasun Pharma

Abhaya Kumar, managing director, Shasun Pharmaceuticals Ltd says that capacity debottlenecking and higher customer demand contributed to 40% y-o-y growth. He also says that the company expects 25% growth in EPS of the company in FY13.

Shasun Pharma plans Rs 250cr expansion

In an interview to CNBC-TV18, Abhaya Kumar, managing director of Shasun Pharmaceuticals says, the company has huge expansion plans. “Shasun is on a very high expansion spree now, investing more than Rs 250 crore in Vizag and in other places. We have raised Rs 50 crore,” he adds.

Shasun Pharma expects 40-50% topline growth in FY12

Abhaya Kumar, managing director of Shasun Pharmaceuticals expects the company's topline to grow 40-50% in FY12. He told CNBC-TV18 in an interview that their confirmed orders for third and fourth quarter are very strong.